{"pmid":32223072,"title":"COVID-19 : Face Masks and Human-to-human Transmission.","text":["COVID-19 : Face Masks and Human-to-human Transmission.","In December 2019, transmission of the novel coronavirus (SARS-CoV-2) that causes coronavirus disease 2019(COVID-19) occurred in Wuhan, China(1) .And later the virus began to be transmitted from person to person(2) .Face masks are a type of personal protective equipment used to prevent the spread of respiratory infectionsit may be effective at helping prevent transmission of respiratory viruses and bacteria(3) .Here, we share a case of face masks are be used to prevent the transmission of COVID-19 infection.","Influenza Other Respir Viruses","Liu, Xiaopeng","Zhang, Sisen","32223072"],"abstract":["In December 2019, transmission of the novel coronavirus (SARS-CoV-2) that causes coronavirus disease 2019(COVID-19) occurred in Wuhan, China(1) .And later the virus began to be transmitted from person to person(2) .Face masks are a type of personal protective equipment used to prevent the spread of respiratory infectionsit may be effective at helping prevent transmission of respiratory viruses and bacteria(3) .Here, we share a case of face masks are be used to prevent the transmission of COVID-19 infection."],"journal":"Influenza Other Respir Viruses","authors":["Liu, Xiaopeng","Zhang, Sisen"],"date":"2020-03-31T11:00:00Z","year":2020,"_id":"32223072","week":"202014|Mar 30 - Apr 05","doi":"10.1111/irv.12740","source":"PubMed","locations":["Wuhan","China(1"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention","Transmission"],"weight":1,"_version_":1662715354762182657,"score":7.277478,"similar":[{"pmid":32127517,"pmcid":"PMC7054527","title":"Transmission routes of 2019-nCoV and controls in dental practice.","text":["Transmission routes of 2019-nCoV and controls in dental practice.","A novel beta-coronavirus (2019-nCoV) caused severe and even fetal pneumonia explored in a seafood market of Wuhan city, Hubei province, China, and rapidly spread to other provinces of China and other countries. The 2019-nCoV was different from SARS-CoV, but shared the same host receptor the human angiotensin-converting enzyme 2 (ACE2). The natural host of 2019-nCoV may be the bat Rhinolophus affinis as 2019-nCoV showed 96.2% of whole-genome identity to BatCoV RaTG13. The person-to-person transmission routes of 2019-nCoV included direct transmission, such as cough, sneeze, droplet inhalation transmission, and contact transmission, such as the contact with oral, nasal, and eye mucous membranes. 2019-nCoV can also be transmitted through the saliva, and the fetal-oral routes may also be a potential person-to-person transmission route. The participants in dental practice expose to tremendous risk of 2019-nCoV infection due to the face-to-face communication and the exposure to saliva, blood, and other body fluids, and the handling of sharp instruments. Dental professionals play great roles in preventing the transmission of 2019-nCoV. Here we recommend the infection control measures during dental practice to block the person-to-person transmission routes in dental clinics and hospitals.","Int J Oral Sci","Peng, Xian","Xu, Xin","Li, Yuqing","Cheng, Lei","Zhou, Xuedong","Ren, Biao","32127517"],"abstract":["A novel beta-coronavirus (2019-nCoV) caused severe and even fetal pneumonia explored in a seafood market of Wuhan city, Hubei province, China, and rapidly spread to other provinces of China and other countries. The 2019-nCoV was different from SARS-CoV, but shared the same host receptor the human angiotensin-converting enzyme 2 (ACE2). The natural host of 2019-nCoV may be the bat Rhinolophus affinis as 2019-nCoV showed 96.2% of whole-genome identity to BatCoV RaTG13. The person-to-person transmission routes of 2019-nCoV included direct transmission, such as cough, sneeze, droplet inhalation transmission, and contact transmission, such as the contact with oral, nasal, and eye mucous membranes. 2019-nCoV can also be transmitted through the saliva, and the fetal-oral routes may also be a potential person-to-person transmission route. The participants in dental practice expose to tremendous risk of 2019-nCoV infection due to the face-to-face communication and the exposure to saliva, blood, and other body fluids, and the handling of sharp instruments. Dental professionals play great roles in preventing the transmission of 2019-nCoV. Here we recommend the infection control measures during dental practice to block the person-to-person transmission routes in dental clinics and hospitals."],"journal":"Int J Oral Sci","authors":["Peng, Xian","Xu, Xin","Li, Yuqing","Cheng, Lei","Zhou, Xuedong","Ren, Biao"],"date":"2020-03-05T11:00:00Z","year":2020,"_id":"32127517","week":"202010|Mar 02 - Mar 08","doi":"10.1038/s41368-020-0075-9","source":"PubMed","locations":["China","Hubei","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Transmission","Prevention"],"weight":1,"_version_":1662334544030728193,"score":164.8236},{"pmid":32213786,"title":"Coronavirus Disease 2019 (COVID-19) and Pregnancy: Responding to a Rapidly Evolving Situation.","text":["Coronavirus Disease 2019 (COVID-19) and Pregnancy: Responding to a Rapidly Evolving Situation.","As the world confronts coronavirus disease 2019 (COVID-19), an illness caused by yet another emerging pathogen (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]), obstetric care providers are asking what this means for pregnant women. The global spread has been swift, and many key questions remain. The case-fatality rate for persons cared for in the United States and whether asymptomatic persons transmit the virus are examples of questions that need to be answered to inform public health control measures. There are also unanswered questions specific to pregnant women, such as whether pregnant women are more severely affected and whether intrauterine transmission occurs. Although guidelines for pregnant women from the American College of Obstetricians and Gynecologists and the Centers for Disease Control and Prevention have been rapidly developed based on the best available evidence, additional information is critically needed to inform key decisions, such as whether pregnant health care workers should receive special consideration, whether to temporarily separate infected mothers and their newborns, and whether it is safe for infected women to breastfeed. Some current recommendations are well supported, based largely on what we know from seasonal influenza: patients should avoid contact with ill persons, avoid touching their face, cover coughs and sneezes, wash hands frequently, disinfect contaminated surfaces, and stay home when sick. Prenatal clinics should ensure all pregnant women and their visitors are screened for fever and respiratory symptoms, and symptomatic women should be isolated from well women and required to wear a mask. As the situation with COVID-19 rapidly unfolds, it is critical that obstetricians keep up to date.","Obstet Gynecol","Rasmussen, Sonja A","Jamieson, Denise J","32213786"],"abstract":["As the world confronts coronavirus disease 2019 (COVID-19), an illness caused by yet another emerging pathogen (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]), obstetric care providers are asking what this means for pregnant women. The global spread has been swift, and many key questions remain. The case-fatality rate for persons cared for in the United States and whether asymptomatic persons transmit the virus are examples of questions that need to be answered to inform public health control measures. There are also unanswered questions specific to pregnant women, such as whether pregnant women are more severely affected and whether intrauterine transmission occurs. Although guidelines for pregnant women from the American College of Obstetricians and Gynecologists and the Centers for Disease Control and Prevention have been rapidly developed based on the best available evidence, additional information is critically needed to inform key decisions, such as whether pregnant health care workers should receive special consideration, whether to temporarily separate infected mothers and their newborns, and whether it is safe for infected women to breastfeed. Some current recommendations are well supported, based largely on what we know from seasonal influenza: patients should avoid contact with ill persons, avoid touching their face, cover coughs and sneezes, wash hands frequently, disinfect contaminated surfaces, and stay home when sick. Prenatal clinics should ensure all pregnant women and their visitors are screened for fever and respiratory symptoms, and symptomatic women should be isolated from well women and required to wear a mask. As the situation with COVID-19 rapidly unfolds, it is critical that obstetricians keep up to date."],"journal":"Obstet Gynecol","authors":["Rasmussen, Sonja A","Jamieson, Denise J"],"date":"2020-03-28T11:00:00Z","year":2020,"_id":"32213786","week":"202013|Mar 23 - Mar 29","doi":"10.1097/AOG.0000000000003873","source":"PubMed","locations":["United States"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1662445896433926144,"score":139.84973},{"pmid":32205090,"title":"Interrupting COVID-19 transmission by implementing enhanced traffic control bundling: Implications for global prevention and control efforts.","text":["Interrupting COVID-19 transmission by implementing enhanced traffic control bundling: Implications for global prevention and control efforts.","We argue that enhanced Traffic Control Bundling (eTCB) can interrupt the community-hospital-community transmission cycle, thereby limiting COVID-19's impact. Enhanced TCB is an expansion of the traditional TCB that proved highly effective during Taiwan's 2003 SARS outbreak. TCB's success derived from ensuring that Health Care Workers (HCWs) and patients were protected from fomite, contact and droplet transmission within hospitals. Although TCB proved successful during SARS, achieving a similar level of success with the COVID-19 outbreak requires adapting TCB to the unique manifestations of this new disease. These manifestations include asymptomatic infection, a hyper-affinity to ACE2 receptors resulting in high transmissibility, false negatives, and an incubation period of up to 22 days. Enhanced TCB incorporates the necessary adaptations. In particular, eTCB includes expanding the TCB transition zone to incorporate a new sector - the quarantine ward. This ward houses patients exhibiting atypical manifestations or awaiting definitive diagnosis. A second adaptation involves enhancing the checkpoint hand disinfection and gowning up with Personal Protective Equipment deployed in traditional TCB. Under eTCB, checkpoint hand disinfection and donning of face masks are now required of all visitors who seek to enter hospitals. These enhancements ensure that transmissions by droplets, fomites and contact are disrupted both within hospitals and between hospitals and the broader community. Evidencing eTCB effectiveness is Taiwan's success to date in containing and controlling the community-hospital-community transmission cycle.","J Microbiol Immunol Infect","Yen, Muh-Yong","Schwartz, Jonathan","Chen, Shey-Ying","King, Chwan-Chuen","Yang, Guang-Yang","Hsueh, Po-Ren","32205090"],"abstract":["We argue that enhanced Traffic Control Bundling (eTCB) can interrupt the community-hospital-community transmission cycle, thereby limiting COVID-19's impact. Enhanced TCB is an expansion of the traditional TCB that proved highly effective during Taiwan's 2003 SARS outbreak. TCB's success derived from ensuring that Health Care Workers (HCWs) and patients were protected from fomite, contact and droplet transmission within hospitals. Although TCB proved successful during SARS, achieving a similar level of success with the COVID-19 outbreak requires adapting TCB to the unique manifestations of this new disease. These manifestations include asymptomatic infection, a hyper-affinity to ACE2 receptors resulting in high transmissibility, false negatives, and an incubation period of up to 22 days. Enhanced TCB incorporates the necessary adaptations. In particular, eTCB includes expanding the TCB transition zone to incorporate a new sector - the quarantine ward. This ward houses patients exhibiting atypical manifestations or awaiting definitive diagnosis. A second adaptation involves enhancing the checkpoint hand disinfection and gowning up with Personal Protective Equipment deployed in traditional TCB. Under eTCB, checkpoint hand disinfection and donning of face masks are now required of all visitors who seek to enter hospitals. These enhancements ensure that transmissions by droplets, fomites and contact are disrupted both within hospitals and between hospitals and the broader community. Evidencing eTCB effectiveness is Taiwan's success to date in containing and controlling the community-hospital-community transmission cycle."],"journal":"J Microbiol Immunol Infect","authors":["Yen, Muh-Yong","Schwartz, Jonathan","Chen, Shey-Ying","King, Chwan-Chuen","Yang, Guang-Yang","Hsueh, Po-Ren"],"date":"2020-03-25T11:00:00Z","year":2020,"_id":"32205090","week":"202013|Mar 23 - Mar 29","doi":"10.1016/j.jmii.2020.03.011","keywords":["COVID-19","Community-hospital-community transmission","Fomite transmission","SARS-CoV","Traffic control bundling","eTCB"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Transmission","Prevention"],"weight":1,"_version_":1662334543411019776,"score":137.04251},{"pmid":32077661,"title":"[Expert consensus on preventing nosocomial transmission during respiratory care for critically ill patients infected by 2019 novel coronavirus pneumonia].","text":["[Expert consensus on preventing nosocomial transmission during respiratory care for critically ill patients infected by 2019 novel coronavirus pneumonia].","Definite evidence has shown that the novel coronavirus (COVID-19) could be transmitted from person to person, so far more than 1,700 bedside clinicians have been infected. A lot of respiratory treatments for critically ill patients are deemed as high-risk factors for nosocomial transmission, such as intubation, manual ventilation by resuscitator, noninvasive ventilation, high-flow nasal cannula, bronchoscopy examination, suction and patient transportation, etc, due to its high possibility to cause or worsen the spread of the virus. As such, we developed this consensus recommendations on all those high-risk treatments, based on the current evidence as well as the resource limitation in some areas, with the aim to reduce the nosocomial transmission and optimize the treatment for the COVID-19 pneumonia patients. Those recommendations include: (1) Standard prevention and protection, and patient isolation; (2) Patient wearing mask during HFNC treatment; (3) Using dual limb ventilator with filters placed at the ventilator outlets, or using heat-moisture exchanger (HME) instead of heated humidification in single limb ventilator with HME placed between exhalation port and mask; avoid using mask with exhalation port on the mask; (4) Placing filter between resuscitator and mask or artificial airway; (5) For spontaneous breathing patients, placing mask for patients during bronchoscopy examination; for patients receiving noninvasive ventilation, using the special mask with bronchoscopy port to perform bronchoscopy; (6) Using sedation and paralytics during intubation, cuff pressure should be maintained between 25-30 cmH(2)O; (7) In-line suction catheter is recommended and it can be used for one week; (8) Dual-limb heated wire circuits are recommended and only changed with visible soiled; (9. For patients who need breathing support during transportation, placing an HME between ventilator and patient; (10) PSV is recommended for implementing spontaneous breathing trial (SBT), avoid using T-piece to do SBT. When tracheotomy patients are weaned from ventilator, HME should be used, avoid using T-piece or tracheostomy mask. (11) Avoid unnecessary bronchial hygiene therapy; (12) For patients who need aerosol therapy, dry powder inhaler metered dose inhaler with spacer is recommended for spontaneous breathing patients; while vibrating mesh nebulizer is recommended for ventilated patients and additional filter is recommended to be placed at the expiratory port of ventilation during nebulization.","Zhonghua Jie He He Hu Xi Za Zhi","32077661"],"abstract":["Definite evidence has shown that the novel coronavirus (COVID-19) could be transmitted from person to person, so far more than 1,700 bedside clinicians have been infected. A lot of respiratory treatments for critically ill patients are deemed as high-risk factors for nosocomial transmission, such as intubation, manual ventilation by resuscitator, noninvasive ventilation, high-flow nasal cannula, bronchoscopy examination, suction and patient transportation, etc, due to its high possibility to cause or worsen the spread of the virus. As such, we developed this consensus recommendations on all those high-risk treatments, based on the current evidence as well as the resource limitation in some areas, with the aim to reduce the nosocomial transmission and optimize the treatment for the COVID-19 pneumonia patients. Those recommendations include: (1) Standard prevention and protection, and patient isolation; (2) Patient wearing mask during HFNC treatment; (3) Using dual limb ventilator with filters placed at the ventilator outlets, or using heat-moisture exchanger (HME) instead of heated humidification in single limb ventilator with HME placed between exhalation port and mask; avoid using mask with exhalation port on the mask; (4) Placing filter between resuscitator and mask or artificial airway; (5) For spontaneous breathing patients, placing mask for patients during bronchoscopy examination; for patients receiving noninvasive ventilation, using the special mask with bronchoscopy port to perform bronchoscopy; (6) Using sedation and paralytics during intubation, cuff pressure should be maintained between 25-30 cmH(2)O; (7) In-line suction catheter is recommended and it can be used for one week; (8) Dual-limb heated wire circuits are recommended and only changed with visible soiled; (9. For patients who need breathing support during transportation, placing an HME between ventilator and patient; (10) PSV is recommended for implementing spontaneous breathing trial (SBT), avoid using T-piece to do SBT. When tracheotomy patients are weaned from ventilator, HME should be used, avoid using T-piece or tracheostomy mask. (11) Avoid unnecessary bronchial hygiene therapy; (12) For patients who need aerosol therapy, dry powder inhaler metered dose inhaler with spacer is recommended for spontaneous breathing patients; while vibrating mesh nebulizer is recommended for ventilated patients and additional filter is recommended to be placed at the expiratory port of ventilation during nebulization."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","date":"2020-02-21T11:00:00Z","year":2020,"_id":"32077661","week":"20208|Feb 17 - Feb 23","doi":"10.3760/cma.j.issn.1001-0939.2020.0020","keywords":["COVID-19","Nosocomial infection","Protective measures","Respiratory therapy","Severe and critical infections"],"source":"PubMed","topics":["Treatment","Prevention"],"weight":1,"_version_":1662334544391438337,"score":133.99998},{"pmid":32134909,"title":"Active Monitoring of Persons Exposed to Patients with Confirmed COVID-19 - United States, January-February 2020.","text":["Active Monitoring of Persons Exposed to Patients with Confirmed COVID-19 - United States, January-February 2020.","In December 2019, an outbreak of coronavirus disease 2019 (COVID-19), caused by the virus SARS-CoV-2, began in Wuhan, China (1). The disease spread widely in China, and, as of February 26, 2020, COVID-19 cases had been identified in 36 other countries and territories, including the United States. Person-to-person transmission has been widely documented, and a limited number of countries have reported sustained person-to-person spread.* On January 20, state and local health departments in the United States, in collaboration with teams deployed from CDC, began identifying and monitoring all persons considered to have had close contact(dagger) with patients with confirmed COVID-19 (2). The aims of these efforts were to ensure rapid evaluation and care of patients, limit further transmission, and better understand risk factors for transmission.","MMWR Morb Mortal Wkly Rep","Burke, Rachel M","Midgley, Claire M","Dratch, Alissa","Fenstersheib, Marty","Haupt, Thomas","Holshue, Michelle","Ghinai, Isaac","Jarashow, M Claire","Lo, Jennifer","McPherson, Tristan D","Rudman, Sara","Scott, Sarah","Hall, Aron J","Fry, Alicia M","Rolfes, Melissa A","32134909"],"abstract":["In December 2019, an outbreak of coronavirus disease 2019 (COVID-19), caused by the virus SARS-CoV-2, began in Wuhan, China (1). The disease spread widely in China, and, as of February 26, 2020, COVID-19 cases had been identified in 36 other countries and territories, including the United States. Person-to-person transmission has been widely documented, and a limited number of countries have reported sustained person-to-person spread.* On January 20, state and local health departments in the United States, in collaboration with teams deployed from CDC, began identifying and monitoring all persons considered to have had close contact(dagger) with patients with confirmed COVID-19 (2). The aims of these efforts were to ensure rapid evaluation and care of patients, limit further transmission, and better understand risk factors for transmission."],"journal":"MMWR Morb Mortal Wkly Rep","authors":["Burke, Rachel M","Midgley, Claire M","Dratch, Alissa","Fenstersheib, Marty","Haupt, Thomas","Holshue, Michelle","Ghinai, Isaac","Jarashow, M Claire","Lo, Jennifer","McPherson, Tristan D","Rudman, Sara","Scott, Sarah","Hall, Aron J","Fry, Alicia M","Rolfes, Melissa A"],"date":"2020-03-06T11:00:00Z","year":2020,"_id":"32134909","week":"202010|Mar 02 - Mar 08","doi":"10.15585/mmwr.mm6909e1","source":"PubMed","locations":["China","United States","- United States","Wuhan"],"countries":["China","United States"],"countries_codes":["CHN|China","USA|United States"],"topics":["Diagnosis","Transmission"],"weight":1,"_version_":1662334543968862211,"score":122.62956}]}